103 related articles for article (PubMed ID: 17984734)
1. Pareto's law and sulfonylureas.
Peiris AN; Micklewright M; Gangadharan V
South Med J; 2007 Nov; 100(11):1072-3. PubMed ID: 17984734
[No Abstract] [Full Text] [Related]
2. Dose-response relationships of sulfonylureas: will doubling the dose double the response?
Rambiritch V; Naidoo P; Butkow N
South Med J; 2007 Nov; 100(11):1132-6. PubMed ID: 17984746
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents.
Davidson MB
West J Med; 1992 Aug; 157(2):199-200. PubMed ID: 1441492
[No Abstract] [Full Text] [Related]
4. Emergency management of oral hypoglycemic drug toxicity.
Rowden AK; Fasano CJ
Emerg Med Clin North Am; 2007 May; 25(2):347-56; abstract viii. PubMed ID: 17482024
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of oral hypoglycemic drugs in the metabolic control of patients with gestational diabetes].
Valdés R E; Soto-Chacón E; Lahsen M R; Barrera H C; Candía P P
Rev Med Chil; 2008 Jul; 136(7):915-20. PubMed ID: 18949170
[TBL] [Abstract][Full Text] [Related]
6. Improving management of type 2 diabetes mellitus: 3. Sulfonylureas.
Samraj GP; Quillen DM; Kuritzky L
Hosp Pract (1995); 1999 Nov; 34(12):129-34, 137, 140. PubMed ID: 10616550
[No Abstract] [Full Text] [Related]
7. If not sulfonylureas, then what?
Leibovitch ER
Geriatrics; 2004 Sep; 59(9):47-8. PubMed ID: 15461239
[No Abstract] [Full Text] [Related]
8. Oral sulfonylureas and CV mortality.
Aronow WS
Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
[No Abstract] [Full Text] [Related]
9. [Maturity onset diabetes of the young (MODY) - screening, diagnostic and therapy].
Kaser S; Resl M
Wien Klin Wochenschr; 2016 Apr; 128 Suppl 2():S204-7. PubMed ID: 27052244
[TBL] [Abstract][Full Text] [Related]
10. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
11. [Pharmacodynamics of second-generation sulfonylureas: dose-effect curve of gliquidone in type II diabetics].
Procacci V; Giovine A; Roberto MG; Ronchi AM; Lasorsa G; Vendemiale G; Stufano N; Altomare E
Boll Soc Ital Biol Sper; 1988 Aug; 64(8):731-8. PubMed ID: 3214573
[No Abstract] [Full Text] [Related]
12. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T
Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
[TBL] [Abstract][Full Text] [Related]
13. Treatment choices for managing hyperglycaemia in patients with type 2 diabetes and moderate to severe renal disease.
Palmer F; Prior SL; Mallipedhi A; Jones DA; Price DE; Stephens JW
Diabetes Res Clin Pract; 2012 Aug; 97(2):e23-4. PubMed ID: 22776145
[No Abstract] [Full Text] [Related]
14. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
15. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
16. Monogenic diabetes: the treatment options.
Owen KR
Diabet Med; 2015 Apr; 32(4):429-30. PubMed ID: 25773279
[No Abstract] [Full Text] [Related]
17. Could FFAR1 assist insulin secretion in type 2 diabetes?
Bailey CJ
Lancet; 2012 Apr; 379(9824):1370-1. PubMed ID: 22374407
[No Abstract] [Full Text] [Related]
18. Comments on type 2 diabetes screening and treatment.
Kolaczynski JW
Am Fam Physician; 2000 Jan; 61(1):49-50. PubMed ID: 10643950
[No Abstract] [Full Text] [Related]
19. Ethnic origin is unrelated to autoimmunity and residual pancreatic function in 471 youth with clinically diagnosed type 2 diabetes.
Gottschalk M; Danne T; Fuerst-Recktenwald S
Pediatr Diabetes; 2009 Jun; 10(4):240-7. PubMed ID: 19493247
[No Abstract] [Full Text] [Related]
20. [Clinical experience with RO 6-4563 (Glibornuride) (a new oral hypoglycemic agent)].
Rodríguez-Miñón JL; Herrera Pombo JL; Marrón JA
Rev Clin Esp; 1971 Dec; 123(5):439-42. PubMed ID: 5160567
[No Abstract] [Full Text] [Related]
[Next] [New Search]
